Notice of WebCast

Oxford Biomedica PLC
24 August 2004


FOR IMMEDIATE RELEASE                                            24 August 2004


                              OXFORD BIOMEDICA PLC


                    Interim Results : Web Cast Notification

                           Wednesday 1 September 2004


On behalf of our client Oxford BioMedica plc, we would like to notify investors
that running simultaneously to the analyst briefing at 10.00 am there will be a
live audio web cast of the results presentation. The results, to be announced on
Wednesday 1 September 2004, are for the six months ended 30 June 2004.


To connect to the web cast facility please go to the Company's website:
www.oxfordbiomedica.co.uk approximately 10 minutes (09:50am) before the start of
the briefing. This will also be available for replay shortly after the
presentation.


The analyst meeting will be held at Buchanan Communications, 107 Cheapside,
London EC2V 6DN.


For further information or any problems please contact:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson
Buchanan Communications                                Tel: [phone]



Notes to editors


Oxford BioMedica


Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange. In addition
to its technical expertise in gene delivery, Oxford BioMedica has in-house
clinical, regulatory and manufacturing know-how. The development pipeline
includes two novel anti-cancer products in clinical trials; and two neurotherapy
products in advanced preclinical development for Parkinson's disease and
retinopathy. The Company is underpinned by an extensive preclinical and research
portfolio and about 70 patent families, which represents one of the broadest
patent estates in the field. The Company has a staff of about 65 split between
its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in
San Diego, California. Oxford. BioMedica has corporate collaborations with
Wyeth, Intervet, Viragen, Merck & Co, Amersham and Kiadis.


Further information is available at http://www.oxfordbiomedica.co.uk.








                      This information is provided by RNS
            The company news service from the London Stock Exchange